Dr. Ron Epelbaum is the Director of the Division of Cancer at Rambam Health Care Campus (RHCC) in Haifa, Israel. This comprehensive cancer center includes Outpatient Clinic and Day-Care Unit which accepts about 30,000 visits of patients and delivers about 20,000 cancer treatments per year, inpatient department contains 46 beds and Radiotherapy Unit with 4 accelerators.
Dr. Epelbaum is a Clinical Associate Professor at the Faculty of Medicine of the Technion, the Israel Institute of Technology, in Haifa, Israel and a full-time cancer specialist at RHCC in Haifa. Dr. Epelbaum graduated from the Faculty of Medicine of the Hebrew Unuversity at Hadassah Hospital, Jerusalem. He completed his residency in oncology at RHCC in 1988 and completed his training as a Research Fellow for one year at Harvard University, in the Laboratory of Clinical Pharmacology at the Dana-Farber Cancer Institute, Boston, USA. His main research interest is treatment of pancreatic cancer and lymphoma, and he has been involved in many phase II-III trials exploring new therapies in these and other solid tumors.
Dr. Epelbaum is a member of several advisory committees in Israel and abroad, and is a member of the European Society foe Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). He was an active member of the Early Clinical Study group (ECSG) of the European Organization for Research on Treatment of Cancer (EORTC). He took part in many phase II and III trials conducted by this group, and chaired some of them. He has contributed about 90 publications in medical journals, including in the European Journal of Cancer, Blood, Cancer and Journal of Nuclear Medicine.